LGM
AKRO

Logos Global Management’s Akero Therapeutics AKRO Stock Holding History

Logos Global Management’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,200,000
Closed -$57M – 70
2025
Q3 		$57M Hold
1,200,000
– – 5.11% 3
2025
Q2 		$64M Hold
1,200,000
– – 7.08% 3
2025
Q1 		$48.6M Buy
1,200,000
+400,000
+50% +$17M 8.64% 3
2024
Q4 		$22.3M Hold
800,000
– – 2.6% 14
2024
Q3 		$23M Hold
800,000
– – 2.48% 16
2024
Q2 		$18.8M Hold
800,000
– – 1.51% 18
2024
Q1 		$20.2M Hold
800,000
– – 1.64% 21
2023
Q4 		$18.7M Buy
800,000
+200,000
+33% +$3.94M 1.74% 18
2023
Q3 		$30.3M Buy
600,000
+80,000
+15% +$3.72M 4.05% 6
2023
Q2 		$24.3M Buy
520,000
+120,000
+30% +$5.5M 3.3% 11
2023
Q1 		$15.3M Hold
400,000
– – 2.19% 19
2022
Q4 		$21.9M Hold
400,000
– – 2.57% 16
2022
Q3 		$13.6M Buy
+400,000
New +$6.12M 1.67% 20

Other funds holding AKRO

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Logos Global Management's AKRO Position: Q4 2025 in Review

Logos Global Management sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 1,200,000 shares — an estimated $57M sold.

Logos Global Management first reported a position in AKRO in Q3 2022 and held it in 13 quarters. The position peaked at $64M in Q2 2025. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.

  • Logos Global Management reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Logos Global Management sold 1,200,000 Akero Therapeutics shares in Q4 2025, an estimated $57M.
  • Logos Global Management first reported a position in Akero Therapeutics in Q3 2022 and held it in 13 quarters.
  • Logos Global Management's Akero Therapeutics position peaked at $64M in Q2 2025.
  • 2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.

Based on Logos Global Management's 13F filing for Q4 2025, filed 17 Feb 2026.